United States

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

3:10am EST
Change (% chg)

€-0.38 (-0.50%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for FREG.DE


Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments... (more)


Beta: 0.58
Market Cap(Mil.): €42,403.50
Shares Outstanding(Mil.): 553.43
Dividend: 0.55
Yield (%): 0.72


  FREG.DE Industry Sector
P/E (TTM): 27.75 31.73 29.68
EPS (TTM): 2.76 -- --
ROI: 9.23 5.63 13.06
ROE: 13.53 8.93 14.19

BRIEF-Fresenius CEO says larger takeovers possible

* Says have looked at biosimilars and don't rule out becoming active in that area

Feb 22 2017

BRIEF-Fresenius FY 2016 sales up 5 pct at 29.1 billion euros

* FY sales 29.1 billion euros ($30.68 billion) (+5 pct, +6 pct in constant currency)

Feb 22 2017

UPDATE 3-New Nestle CEO ditches elusive sales target

* New CEO says not right time for big M&A (Adds fresh CEO, analyst comments, shares)

Feb 16 2017

BRIEF-Fresenius says Quironsalud to be consolidated as of Feb. 1

* Says Quironsalud will be consolidated as of February 1, 2017

Jan 31 2017

BRIEF-Fresenius SE to issue 500 mln eur convertible bonds

* Fresenius announces issuance of equity-neutral convertible bonds

Jan 19 2017

BRIEF-Fresenius SE places EUR2.6 bln in notes to fund Quirónsalud purchase

* Says places four tranches with volumes of 700 and 500 million

Jan 17 2017

BRIEF-Fresenius sees further growth prospect for Kabi unit

* CEO says still sees opportunities for Kabi to grow, both organically and via M&A

Oct 27 2016

Fresenius wins injunction barring generic thyroid hormone injection

A federal judge has barred generic drug maker Fera Pharmaceuticals LLC from selling a generic version of Fresenius Kabi's injectable thyroid hormone levothyroxine, finding that Fresenius was likely to win a patent lawsuit against Fera.

Sep 22 2016

Fitch: Fresenius' Quironsalud Buy Adds Scale, Diversification; No Rating Impact

(The following statement was released by the rating agency) LONDON, September 06 (Fitch) Fitch Ratings says German healthcare group Fresenius SE & Co KGaA's (FSE; BBB-/Stable, including Fresenius Medical Care AG & Co. KGaA (FMC), together Fresenius) acquisition of Spain-based private hospital group Quironsalud for an estimated EUR5.76bn, will have no impact on its existing ratings. Despite being predominantly debt-funded, the transaction will use headroom available under the current rating,

Sep 06 2016

UPDATE 2-Germany's Fresenius takes expansion plans to new heights with $6.4 bln Spanish healthcare acquisition

* Price includes assumed debt, buys from CVC, senior managers

Sep 06 2016

More From Around the Web

Earnings vs. Estimates